Micro-molecule polypeptide NEAT1-31 and application and product thereof

Through the combined use of small molecule polypeptide NEAT1-31 and anti-CD47 antibodies, the problem of insufficient phagocytic ability of macrophages in the prior art has been solved, significantly enhanced the phagocytic ability of cancer cells, and provided a new method for treating tumors. It is an effective solution for patients with drug-resistant immune checkpoint blockade therapy.

CN118994325AActive Publication Date: 2024-11-22WOMEN & CHILDRENS MEDICAL CENTER AFFILIATED WITH GUANGZHOU MEDICAL UNIVERSITY
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411242937.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-05
Publication Date
2024-11-22
Estimated Expiration
2044-09-05

AI Technical Summary

Technical Problem

Existing immune checkpoint blocking therapy has limited effect on drug-resistant patients and lacks effective phagocytosis activators to enhance the phagocytosis of macrophages, resulting in poor cancer treatment.

Method used

A small molecule peptide NEAT1-31 was developed to enhance the phagocytosis and elimination of cancer cells by improving the phagocytosis and use in combination with anti-CD47 antibodies.

Benefits of technology

NEAT1-31 significantly improves the phagocytic ability of macrophages and works in concert with anti-CD47 antibodies to inhibit tumor progression and brings new therapeutic hopes to patients with drug-resistant immune checkpoint blockade therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994325A_ABST
    Figure CN118994325A_ABST
Patent Text Reader

Abstract

The invention provides a small molecule polypeptide NEAT1-31 as well as application and a product thereof, and relates to the technical field of biology. The amino acid sequence of the small molecule polypeptide NEAT1-31 provided by the invention is as shown in SEQ ID NO. 1. The research of the inventor finds that Neat1-31 has the effect of promoting phagocytosis in vivo and in vitro. And moreover, the Neat1-31 and the anti-CD47 antibody are proved to have a synergistic effect, and the Neat1-31 and the anti-CD47 antibody jointly inhibit tumor progression. A new direction is provided for tumor treatment, and a new hope is brought to a patient with drug resistance of an immune checkpoint blocking (ICB) therapy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to a small molecule polypeptide NEAT1-31 and applications and products thereof. Background Art

[0002] Advances in single-cell multi-omics have provided a deeper understanding of the complex interactions between different immune cell subsets and tumor cells in the tumor microenvironment, and the results offer promising insights into overcoming these challenges. In addition to their crucial role in innate immunity, macrophages are also integrally involved in adaptive immunity, presenting antigens through phagocytosis, a multistep cellular process involving target cell recognition. Cellular phagocytosis and lysosomal digestion are regulated by receptor-ligand interactions between target cells and phagocytes, known as "eat me" signals. Once the innate "eat me" signal is activated by immunoreceptor tyrosine-based activation motifs (ITAMs), the phagocyte cytoskeleton is remodeled to facilitate phagocytosis. In contrast, cancer cells evade immune clearance with the help of anti-phagocytic molecules, including CD47, CD24, PD-L1, MHC-I, STC-1, and GD2, known as "don't eat me" signals. Most phagocytosis-related ICB therapies focus on blocking "don't eat me" signals, such as CD47 and PD-L1.

[0003] Although immune checkpoint blockade (ICB) therapy has achieved unprecedented success in suppressing cancer by enhancing T cell responses, drug resistance prevents most patients from benefiting from this therapy. Furthermore, there are currently few reports on phagocytosis activators.

[0004] In view of this, the present invention is proposed. Summary of the Invention

[0005] The first object of the present invention is to provide a small molecule polypeptide NEAT1-31, which has the function of improving the phagocytic ability of macrophages and treating cancer, so as to solve the above problems.

[0006] The second object of the present invention is to provide the use of the above-mentioned small molecule polypeptide NEAT1-31 in improving the phagocytic ability of macrophages.

[0007] The third object of the present invention is to provide the use of the above-mentioned small molecule polypeptide NEAT1-31 in the preparation of drugs for treating cancer.

[0008] The fourth object of the present invention is to provide the use of the above-mentioned small molecule polypeptide NEAT1-31 in combination with anti-CD47 antibodies in the preparation of drugs for treating cancer.

[0009] The fifth object of the present invention is to provide a phagocyte activator.

[0010] The sixth object of the present invention is to provide a drug for treating cancer.

[0011] In order to achieve the above objectives, the following technical solutions are adopted:

[0012] In a first aspect, the present invention provides a small molecule polypeptide NEAT1-31, the amino acid sequence of the small molecule polypeptide NEAT1-31 is shown in SEQ ID NO.1.

[0013] In a second aspect, the present invention provides the use of the above-mentioned small molecule polypeptide NEAT1-31 in improving the phagocytic ability of macrophages.

[0014] In a third aspect, the present invention provides the use of the above-mentioned small molecule polypeptide NEAT1-31 in the preparation of drugs for treating cancer.

[0015] As a further technical solution, the cancer includes breast cancer, gastric cancer, colon cancer, low-grade glioma, glioblastoma, bladder urothelial carcinoma, liver cancer, lung cancer, pancreatic ductal adenocarcinoma and ovarian cancer.

[0016] In a fourth aspect, the present invention provides the use of the above-mentioned small molecule polypeptide NEAT1-31 in combination with an anti-CD47 antibody in the preparation of a drug for treating cancer.

[0017] As a further technical solution, the cancer includes breast cancer, gastric cancer, colon cancer, low-grade glioma, glioblastoma, bladder urothelial carcinoma, liver cancer, lung cancer, pancreatic ductal adenocarcinoma and ovarian cancer.

[0018] In a fifth aspect, the present invention provides a phagocyte activator, which comprises the small molecule polypeptide NEAT1-31.

[0019] In a sixth aspect, the present invention provides a drug for treating cancer, comprising the aforementioned phagocyte activator.

[0020] As a further technical solution, the drug also includes an anti-CD47 antibody.

[0021] As a further technical solution, the cancer includes breast cancer, gastric cancer, colon cancer, low-grade glioma, glioblastoma, bladder urothelial carcinoma, liver cancer, lung cancer, pancreatic ductal adenocarcinoma and ovarian cancer.

[0022] Compared with the prior art, the present invention has the following beneficial effects:

[0023] The inventors of the present invention have discovered that the small molecule peptide NEAT1-31 promotes phagocytosis both in vivo and in vitro. They have also demonstrated synergistic effects between Neat1-31 and anti-CD47 antibodies, jointly inhibiting tumor progression. This provides a new avenue for cancer treatment and offers hope for patients resistant to immune checkpoint blockade (ICB) therapy. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] In order to more clearly illustrate the specific embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the specific embodiments or the description of the prior art. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0025] Figure 1 Schematic representation of ribosome profiling of phagocytes, macrophages, and cancer cells;

[0026] Figure 2 Figure 1 shows the ribosome profiling analysis of phagocytes, including: B. Venn diagram of dysregulated mRNA, lincRNA, 3'UTR, and 5'UTR; C. Relative expression distribution of mRNA, lincRNA, 3'UTR, and 5'UTR; D. Pie chart distribution of mRNA, lincRNA, 3'UTR, and 5'UTR; E. Mapping of ribosome protected fragments (RPFs) to transcripts, showing the percentage of RPF mapping for each ORF; F. Length distribution of lincRNA; G. Phagocytic expression and ORF score of each ORF, with ORF score on the x-axis and relative phagocytic expression on the y-axis.

[0027] Figure 3NEAT1-31, encoded by LincNeat1, is enriched in anti-tumor macrophages, indicating a better response to ICB treatment; A. RFP density of LincNEAT1 was derived from ribosome analysis; B. Left: Flag knock-in and LincNeat1 knock-out cell lines were established in HEK293T cells, and Flag and NEAT1-31 were detected by immunoblotting; Right: THP1-induced macrophages (M0 / M1 / M2) were used to detect NEAT1-31; C. NEAT1-31 expression in anti- / pro-tumor macrophages was detected by flow cytometry. Distribution; D. Macrophages from different sample types were divided into anti-tumor and pro-tumor macrophages, and NEAT1-31 expression was detected; E. The percentage of NEAT1-31-positive macrophages from different cancer types; F. The percentage of NEAT1-31-positive macrophages in anti-tumor and pro-tumor macrophages from different tumor types; G. The ratio of NEAT1-31+ macrophages to CD45 cells was calculated by flow cytometry, and patients were divided into NEAT1-31 low / high groups, with the average ratio of NEAT1-31+ macrophages to CD45 cells as the critical value. The response rate (RR) of ICB treatment was calculated for each cohort;

[0028] Figure 4 NEAT1-31 and anti-CD47 antibodies inhibit tumor progression through synergistic effects;

[0029] Figure 5 To verify that NEAT1-31 and anti-CD47 antibodies inhibit tumor progression through synergistic effects. DETAILED DESCRIPTION

[0030] Below in conjunction with embodiment and example, embodiment of the present invention is described in detail, but those skilled in the art will appreciate that the following embodiment and example are only used to illustrate the present invention, and should not be considered as limiting the scope of the present invention. Based on the embodiment in the present invention, all other embodiments obtained by those of ordinary skill in the art without making creative work premise all fall within the scope of protection of the present invention. Unspecified conditions are carried out according to the conditions of normal conditions or manufacturer's recommendations. Reagents used or instruments not specified by the manufacturer are conventional products that can be purchased commercially.

[0031] In a first aspect, the present invention provides a small molecule polypeptide NEAT1-31, the amino acid sequence of the small molecule polypeptide NEAT1-31 is shown in SEQ ID NO.1:

[0032] MGIVGREWARCLYYMCDLKTLLGSELRLLNW (SEQ ID NO. 1).

[0033] The small molecule polypeptide NEAT1-31 has the functions of improving the phagocytic ability of macrophages and treating cancer.

[0034] In a second aspect, the present invention provides the use of the above-mentioned small molecule polypeptide NEAT1-31 in improving the phagocytic ability of macrophages.

[0035] The small molecule polypeptide NEAT1-31 provided by the present invention has the effect of improving the phagocytic ability of macrophages, and therefore can be used to improve the phagocytic ability of macrophages.

[0036] In a third aspect, the present invention provides the use of the above-mentioned small molecule polypeptide NEAT1-31 in the preparation of drugs for treating cancer.

[0037] The small molecule polypeptide NEAT1-31 provided by the present invention has the effect of treating cancer and can therefore be used to prepare drugs for treating cancer.

[0038] In some optional embodiments, the cancer includes but is not limited to breast cancer, gastric cancer, colon cancer, low-grade glioma, glioblastoma, bladder urothelial carcinoma, liver cancer, lung cancer, pancreatic ductal adenocarcinoma and ovarian cancer.

[0039] In a fourth aspect, the present invention provides the use of the above-mentioned small molecule polypeptide NEAT1-31 in combination with an anti-CD47 antibody in the preparation of a drug for treating cancer.

[0040] The inventors have discovered that the small molecule polypeptide NEAT1-31 and the anti-CD47 antibody have a synergistic effect in cancer treatment, and the combination of the two can further improve the effect of cancer treatment.

[0041] In some optional embodiments, the cancer includes but is not limited to breast cancer, gastric cancer, colon cancer, low-grade glioma, glioblastoma, bladder urothelial carcinoma, liver cancer, lung cancer, pancreatic ductal adenocarcinoma and ovarian cancer.

[0042] In a fifth aspect, the present invention provides a phagocyte activator, which comprises the small molecule polypeptide NEAT1-31.

[0043] The phagocyte activator has the function of promoting macrophage phagocytosis.

[0044] In a sixth aspect, the present invention provides a drug for treating cancer, comprising the aforementioned phagocyte activator.

[0045] This drug can be used to treat cancer.

[0046] In some optional embodiments, the drug further comprises an anti-CD47 antibody.

[0047] The small molecule peptide NEAT1-31 and anti-CD47 antibody have a synergistic effect, which can further improve the therapeutic effect of cancer.

[0048] In some optional embodiments, the cancer includes but is not limited to breast cancer, gastric cancer, colon cancer, low-grade glioma, glioblastoma, bladder urothelial carcinoma, liver cancer, lung cancer, pancreatic ductal adenocarcinoma and ovarian cancer.

[0049] The present invention is further described below by way of specific examples. However, it should be understood that these examples are merely provided for more detailed description and are not to be construed as limiting the present invention in any form.

[0050] Example 1

[0051] To identify potential phagocyte activators, the inventors first established an in vitro phagocytosis assay as follows.

[0052] Peripheral blood was collected and peripheral blood mononuclear cells (PBMCs) were isolated and then cultured in ImmunoCult TM -SF macrophage culture medium, and then labeled with CellTraceTM Blue (Thermo Fisher, cat# C34568). Similarly, MDA-MB-231 breast cancer cells were labeled with 5 (6) -carboxyfluorescein diacetate succinyl ester (CFSE), and macrophages were incubated with MDA-MB-231 cells for 2 hours and subjected to fluorescence activated cell sorting (FACS) analysis. Cells labeled with blue cell tracker and CFSE were considered to be phagocytic cells. In addition to conventional FACS, the inventors also applied mild trypsinization to avoid cell adhesion. Only cells with blue cell tracker were identified as macrophages without phagocytic ability, and equal amounts of phagocytes, macrophages and MDA-MB231 cells were collected from 100 donors and subjected to ribosome profiling analysis (such as Figure 1As shown). Ribosome protected fragments (RPFs) were collected and transcript mapped. Reading frames mapped to the transcribed regions showed clear 3-nt periodicity, indicating reliable quality control. Further application of principal component analysis (PCA) showed that RPF features could distinguish cancer cells, phagocytes, and macrophages. For further confirmation, relative FPKM and RPF counts were used to analyze well-studied phagocytic checkpoints. The "don't eat me" markers CLEC-1, Siglec-10, SIRPα, LILRB1, and PD1 were significantly more expressed in macrophages than in phagocytes, and the above data all showed reliable specificity and sensitivity. Therefore, the inventors used separate analysis procedures. However, phagocytosis actually involves two cell types, phagocytes "eat" cancer cells. To determine the reliability of using phagocyte activators, the inventors used a rigorous analysis process. First, by comparing phagocytes with cancer cells, phagocyte-specific genes were identified (FPKM = 0 for MDA-MB-231 cells, FPKM > 0 for phagocytes). Next, the expression of phagocyte-specific genes in phagocytes and macrophages was compared, and finally, the phagocytic activator was identified. Based on this, a Venn diagram of mRNA, lincRNAs, 3'UTRs and 5'UTRs was constructed. A total of 2606 potential phagocyte activators were identified, including 7 mRNAs, 750 lincRNAs, 85 3'UTRs and 1764 5'UTRs (e.g. Figure 2 Summarizing the expression levels of each group, the reading frame in the 5'UTR had the highest expression level (as shown in B). Figure 2 Most RPFs are derived from 3'UTRs, accounting for 67.69% of all RPFs (as shown in C in Figure 2). Figure 2 Approximately 67.69% of RPFs were mapped to 3'UTRs, 31.2% of RPFs were mapped to lincRNAs, and less than 10% of RPFs were mapped to mRNAs and 5'UTRs (as shown in D). Figure 2 The distribution and length of lincORFs were analyzed, and the number of lincORF peaks at 80-130 bp was determined (as shown in E in Figure 1). Figure 2 The ORF score was calculated to determine the extent of active translation, and the expression level was determined to verify the biological significance of each group. The putative lincRNA ORF (lincNEAT1-31aa) that met the ORF score and phagocyte expression criteria was significantly upregulated in phagocytes (phagocyte FPKM = 11.62, cancer FPKM = 0, macrophage FPKM = 0.65, P = 3.01E-06, FC = 4.16, where the P value is a numerical value in statistics, representing the significance of the difference, and FC refers to the fold change) (as shown in Figure 5). Figure 2 G in the figure).

[0053] The linNEAT1 ORF is located in the chromosomal region 2833-2928 of the ENST 00000645023 transcript, and ribosome analysis predicted that this ORF encodes a 31-amino acid micropeptide (hereafter referred to as NEAT1-31) (e.g. Figure 3 As shown in A in ). To confirm the translational role of NEAT1-31, the inventors established a flag knock-in and knock-out system in HEK293T cells. Since there is no effective strategy to induce phagocytes, the inventors treated THP1 cells (human monocytes) with phorbol 12-myristate 13-acetate (PMA) (a phorbol ester, an activator of protein kinase C and SphK), lipopolysaccharide (LPS) or IL4 to induce macrophages. NEAT1-31 was detected by immunoblotting using anti-flag antibodies, and specific monoclonal antibodies (anti-NEAT1-31 antibodies) were generated to directly detect NEAT1-31 (as shown in A in ). Figure 3 (as shown in B in the figure). Figure 3 In the left figure of B: WT is blank HEK293T cells without treatment, KI is HEK293T cells with Flag knocked in, and KO is HEK293T cells with LincNeat1 knocked out. Flag and NEAT1-31 were detected by immunoblotting. Right figure: THP1 was induced into macrophages (M0 / M1 / M2, where M0, M1, and M2 are different types of macrophages), and NEAT1-31 was detected. To further confirm, the inventors used FACS to determine the proportion of NEAT1-31+ in different macrophages. Next, macrophages were collected from healthy donors and detected with NEAT1-31, iNOS, and CD206 antibodies. NEAT1-31 is abundantly expressed in iNOS+ macrophages and hardly expressed in CD206+ macrophages. iNOS and CD206 are two widely used classic markers of anti-tumor / proto-tumor (AT / PT) macrophages (such as Figure 3 Next, different tumor samples were collected and FACS analyzed for NEAT1-31+ macrophages (20 patients each: BRCA, breast cancer; STCA, gastric cancer; COCA, colon cancer; LGG, low-grade glioma; GBM, glioblastoma; BLCA, bladder urothelial carcinoma; HC, liver cancer; LUCA, lung cancer; PDAC, pancreatic ductal adenocarcinoma; OC, ovarian cancer). NEAT1-31+ macrophages accounted for 0-20% of the total macrophages in different tumors; the proportion of NEAT1-31+ macrophages was the highest in BRCA, while the infiltration rate of NEAT1-31+ macrophages in COCA and GBM was very low (as shown in Figure 2). Figure 3(D, E in Figure 1). The macrophages were then divided into anti-tumor macrophages and pro-tumor macrophages (anti-tumor macrophages refer to M1 macrophages, which usually express iNOS; pro-tumor cells refer to M2 macrophages, which usually express CD206). NEAT1-31+ macrophages were detected in each group. The results showed that NEAT1-31 was specifically enriched in anti-tumor macrophages of different tumors (e.g. Figure 3 As shown in F in the figure). Patients receiving immunotherapy were enrolled, tumor samples were collected, and infiltrating lymphocytes were isolated. The ratio of NEAT1-31+ macrophages to CD45 cells was calculated by flow cytometry, and patients were divided into NEAT1-31 low / high groups, with the average ratio of NEAT1-31+ macrophages to CD45 cells as the critical value. The effective rate (RR) of ICB treatment was calculated for each cohort, and the effective rate of the NEAT1-31 high group was greater than that of the NEAT1-31 low group. In summary, these findings reveal that lincNEAT1 encodes NEAT1-31, which is specifically enriched in anti-tumor macrophages and predicts a good ICB response in a variety of cancers (such as Figure 2 G in the figure).

[0054] CD47 is one of the most important phagocytic immune checkpoints, and specific blocking of CD47 by antibodies can promote phagocytosis. In order to verify the clinical application of NEAT1-31 in promoting phagocytosis, we treated donor-derived macrophages (DDMs) with NEAT1-31, regardless of whether they contained CD47 antibodies. The cells were subjected to phagocytosis experiments: first, enough macrophages and tumor cells were cultured, and then tumor cells (MDA-MB-231 breast cancer cells or human glioma cells U251) were labeled with CFSE, and macrophages were labeled with blue. These labeled macrophages and tumor cells were co-cultured, and after sufficient phagocytosis, the phagocytosis rate was calculated by flow cytometry. The results showed that NEAT1-31 and anti-CD47 antibodies promoted cell phagocytosis as expected, and NEAT1-31 plus anti-CD47 antibodies had a synergistic effect ( Figure 4 AC in). Figure 4 Figures A and B show that DDM1 and DDM2 (DDM1 and DDM2 are macrophages derived from different donors) were treated with NEAT 1-31, anti-CD47 antibody, or their combination. In vitro phagocytosis assays were performed, and phagocytic cells were detected by flow cytometry. Figure 4 The C in Figure 4Statistical graphs of A and B in . Next, we established a quasi-orthotopic (implanted into the renal capsule) xenograft model. The specific experimental steps included implanting 1×10^6 MDA-MB-231-Luc or 1×10^6 U251 tumor cells into the renal capsule. Mice carrying tumor cells were treated with IgG or anti-CD 47 antibodies. Monocytes were then extracted from the blood of the mice and sorted, leaving macrophages, which were transfected with Neat-31 overexpression plasmids and then infused back into the mice through the tail vein. A total of 400 μg of anti-CD 47 (clone B6.H12, Bio X Cell) was injected intraperitoneally into the mice every other day. Bioluminescence imaging (BLI) and IVIS instruments (PhotoSound PAFT / 256) were used to detect the growth of tumor xenografts (such as Figure 4 E in ), measure the statistical relative flux intensity (as Figure 4 As shown in F in the figure, BLI technology enables cells to express luciferase by inserting the luciferase gene into the cell chromosome DNA. When luciferin is given exogenously, luciferase catalyzes the oxidation reaction of luciferin in the presence of ATP and oxygen, producing a luminescent phenomenon. This luminescence occurs only in living cells, and the intensity of the light is linearly related to the number of labeled cells. Therefore, by measuring the intensity of the light flux, the size and growth of the tumor can be quantitatively assessed. ). Measure and statistically analyze the overall survival time (such as Figure 4 The results showed that both NEAT1-31 and anti-CD47 could promote the elimination of cancer cells and prolong the overall survival time of breast cancer and GBM mice ( Figure 4 DG in ). Figure 4 D in the figure illustrates a combined therapy strategy in which mice were treated with either anti-CD47 antibodies or NEAT 1-31-treated macrophages. These findings were further confirmed in the C57 model (referring to the experimental procedure above, except that ordinary mice were replaced with C57 mice), where NEAT1-31 and anti-CD47 antibodies synergistically inhibited tumor progression ( Figure 5 AC in).

[0055] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the above embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the above embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A small molecule polypeptide NEAT1-31, characterized in that: The amino acid sequence of the small molecule polypeptide NEAT1-31 is shown in SEQ ID NO.

1.

2. Use of the small molecule polypeptide NEAT1-31 according to claim 1 in improving the phagocytic ability of macrophages.

3. Use of the small molecule polypeptide NEAT1-31 according to claim 1 in the preparation of drugs for treating cancer.

4. The use according to claim 3, characterized in that: The cancers include breast cancer, gastric cancer, colon cancer, low-grade glioma, glioblastoma, bladder urothelial carcinoma, liver cancer, lung cancer, pancreatic ductal adenocarcinoma, and ovarian cancer.

5. Use of the small molecule polypeptide NEAT1-31 according to claim 1 in combination with an anti-CD47 antibody in the preparation of a drug for treating cancer.

6. The use according to claim 5, characterized in that: The cancers include breast cancer, gastric cancer, colon cancer, low-grade glioma, glioblastoma, bladder urothelial carcinoma, liver cancer, lung cancer, pancreatic ductal adenocarcinoma, and ovarian cancer.

7. A phagocyte activator, characterized in that The phagocyte activator comprises the small molecule polypeptide NEAT1-31 according to claim 1.

8. A drug for treating cancer, characterized in that: The drug comprises the phagocyte activator according to claim 7.

9. The drug according to claim 8, characterized in that The medicament also includes anti-CD47 antibodies.

10. The drug according to claim 8, characterized in that The cancers include breast cancer, gastric cancer, colon cancer, low-grade glioma, glioblastoma, bladder urothelial carcinoma, liver cancer, lung cancer, pancreatic ductal adenocarcinoma, and ovarian cancer.

Citation Information

Patent Citations

  • Application of lncRNA NEAT1_1

    CN113564255A

  • Application of LncRNA NEAT1-2 detection reagent in HFRS condition assessment

    CN115287344A

  • Nucleic acid and application thereof in preparation of antitumor drugs

    CN117643594A